What does this goal involve?
Longevity research in the context of peptides and biomarkers focuses on what the field calls the "hallmarks of aging" , the biological processes that accumulate damage and drive functional decline over time. These include chronic low-grade inflammation (inflammaging), declining NAD+ levels, mitochondrial dysfunction, cellular senescence, telomere shortening, and loss of proteostasis. Research protocols targeting longevity typically attempt to modulate one or more of these hallmarks simultaneously rather than targeting a single mechanism in isolation , which is why the biomarker panel for longevity research is broader and more multi-system than goal-specific panels.
The central challenge of longevity research is the absence of lifespan as a practical endpoint , human trials cannot track actual longevity in reasonable timeframes. As a result, all longevity research relies on surrogate markers: biomarkers of biological aging (hs-CRP, HbA1c, homocysteine, DHEA-S), functional performance measures, and mechanistic endpoints like telomere length or senescence markers. This is why longevity research findings require particularly careful interpretation , a compound that improves a surrogate aging marker may or may not translate to meaningful healthspan extension, and the research literature is explicit about this limitation.
NAD+ and mitochondrial peptide research (MOTS-c, SS-31) represents one of the most active and mechanistically compelling areas of longevity science. NAD+ depletion with age impairs sirtuins, DNA repair, and mitochondrial function simultaneously , making NAD+ precursors and supportive peptides central to modern longevity protocols. Epithalon's place in longevity research is anchored by its telomere biology: documented activation of telomerase and telomere length extension in both in vitro and preclinical studies, with some human data from Eastern European researchers, represents a mechanistic approach to one of the core hallmarks of aging.
Biomarkers to establish before exploring this goal.
Research protocols for this goal area typically reference the following biomarkers as baseline context. Testing these first gives you and your healthcare provider the most relevant starting information.
Age-related GH/IGF-1 decline is one of the most studied contributors to the aging phenotype , establishing baseline IGF-1 identifies where on the GH decline curve a subject sits and informs GH secretagogue research relevance and dosing context.
Inflammaging , chronic low-grade inflammation , is one of the best-characterized hallmarks of aging and a strong predictor of all-cause mortality in aging populations. hs-CRP is the standard clinical proxy for this process and is essential in every longevity panel.
Glycation , the non-enzymatic binding of glucose to proteins , is a direct aging mechanism that damages tissues over time. HbA1c is the clinical measure of glycation burden; maintaining optimal HbA1c is consistently associated with reduced biological aging in the literature.
Vitamin D deficiency is strongly associated with accelerated biological aging, all-cause mortality, and immune senescence , its ubiquity as a longevity-relevant variable makes it a non-negotiable baseline in any longevity panel regardless of other protocol choices.
Cardiovascular disease is the leading cause of mortality in aging populations , ApoB is the most accurate predictor of atherosclerotic risk and a key surrogate endpoint in longevity research protocols targeting cardiovascular aging.
DHEA-S declines ~2–3% per year from peak in the mid-20s , its trajectory is one of the most consistent biological aging clocks, and low DHEA-S is associated with all-cause mortality risk in aging populations. A key biomarker for longevity-focused panels.
Elevated homocysteine is independently associated with cardiovascular disease, cognitive decline, and all-cause mortality , it is the most correctable advanced aging biomarker (through B-vitamin support) and one of the highest signal-to-cost markers in longevity panels.
What does the research focus on for this goal?
NAD+ research for longevity is anchored in the biology of sirtuins , a family of proteins that regulate DNA repair, gene expression, and mitochondrial biogenesis , and their dependence on NAD+ as a cofactor. NAD+ levels decline approximately 50% between ages 40 and 60 in most tissues, and this decline correlates with the functional decline of sirtuins and the accumulation of DNA damage, impaired mitochondrial function, and increased cellular senescence. NAD+ precursor supplementation and NAD+ peptide research focuses on restoring this cofactor availability to maintain sirtuin activity and the cellular repair processes it governs.
MOTS-c is a mitochondria-derived peptide that has emerged as a significant longevity research target due to its role in metabolic regulation, AMPK activation, and what researchers describe as exercise-mimetic effects on metabolism. Studies show MOTS-c levels decline with age and are restored by exercise , making it a candidate for metabolic longevity support in populations with limited exercise capacity. SS-31 (Elamipretide) works at a more fundamental level , targeting cardiolipin on the inner mitochondrial membrane to improve electron transport chain efficiency and reduce mitochondrial reactive oxygen species production. It is the most mechanistically targeted mitochondrial longevity peptide currently in the research pipeline.
Epithalon's longevity research case is built on telomere biology and pineal gland function. Telomerase activation by Epithalon has been documented in cell culture and preclinical studies, with the peptide appearing to restore telomere length erosion rates. Separately, its effect on melatonin secretion from the pineal gland connects to circadian regulation, immune function, and antioxidant capacity , all of which decline with age and contribute to the aging phenotype. The combination of telomere and circadian biology mechanisms makes Epithalon one of the most multi-mechanistic peptides in the longevity research space, despite remaining in the preliminary evidence category for human lifespan endpoints.
Peptides commonly researched for this goal.
The peptides below appear in research literature in connection with this goal. This is not a recommendation to use any of these compounds. Always consult a licensed healthcare provider.
GHRH analog with the strongest clinical track record for GH axis restoration , GH decline is a central feature of the aging phenotype and Sermorelin's well-characterized safety and efficacy for GH support makes it the anchor of GH-axis longevity research.
NAD+ cofactor supplementation is studied for restoration of sirtuin activity, DNA repair capacity, and mitochondrial biogenesis , supported by mechanistic and preclinical research evidence with growing human data; the most extensively researched longevity intervention after caloric restriction.
Mitochondria-derived peptide that activates AMPK, improves insulin sensitivity, and replicates metabolic effects of exercise , declining MOTS-c levels with age correlate with metabolic aging, positioning it as a longevity target for metabolic healthspan extension.
Thymic peptide with FDA-approved analogs in multiple countries , studied for immune senescence reversal through thymic function support. Age-related thymic involution and declining T-cell diversity are well-characterized longevity vulnerabilities that Thymosin Alpha-1 research addresses directly.
Copper-binding peptide that declines dramatically with age , research documents its role in activating over 4,000 genes including those governing tissue repair, antioxidant defense, and anti-inflammatory signaling, supporting it as a broad-spectrum tissue longevity agent.
Tetrapeptide studied for telomerase activation and telomere length maintenance , the only peptide with documented telomere-lengthening effects in human cells, placing it at the intersection of the two most discussed longevity mechanisms: telomere biology and epigenetic aging.
What research protocols typically examine.
Timeline
Longevity research operates on the longest timescales of any goal category , surrogate marker changes are assessed at 6–24 month intervals. Meaningful biological aging clock changes (epigenetic age, telomere length) require multi-year protocols to detect with confidence.
Monitoring
Full longevity panel: IGF-1, hs-CRP, HbA1c, fasting insulin, Vitamin D, ApoB, DHEA-S, homocysteine. Advanced protocols add epigenetic age testing (Horvath clock), telomere length assays, and comprehensive metabolic panels at 6–12 month intervals.
Limitations
No human longevity research uses lifespan as an endpoint , all findings rely on surrogate aging markers. The translation from surrogate marker improvement to actual healthspan extension is assumed but not proven. Longevity research requires the most conservative interpretation of any goal category.